NEW YORK ( TheStreet) -- CHANGE IN RATINGSConstellation Energy ( CEG) downgraded at Barclays to Equal Weight from Overweight due to uncertainty on financial reform impacts. Price target dropped to $36 from $39. Chesapeake ( CPK) upgraded at Baird from Neutral to Outperform. $35 price target. Valuation call, given a more upbeat outlook for the industry. Dominion Resources ( D) upgraded at Morgan Stanley from Underweight to Equal-weight. $39 price target. Company deserves a premium multiple. Dell ( DELL) upgraded at UBS from Neutral to Buy. $15.50 price target. Estimates cut because of market share losses, but the company can still benefit from the PC refresh cycle. Entertainment Properties Trust ( EPR) upgraded at Citi to Buy from Hold on dividend growth and reduced risk profile. Maintain $46 price target. Ford ( F) upgraded at Citi to Hold from Sell. Valuation call. Maintain $10 price target. Forest Labs ( FRX) initiated at Credit Suisse with a Neutral rating and $27 price target. FRX has both one of the largest patent cliff and pipeline replacement potential. Hess ( HES) downgraded at Morgan Stanley to Equal-weight. $65 price target. Company is hurt by uncertainty in the Gulf and has limited near-term drilling prospects. Heartland Express ( HTLD) initiated at Piper Jaffray. Initiated with a Neutral rating and $17 price target. Introduces 2010 EPS estimates of $0.62. Ironwood Pharmaceuticals ( IRWD) initiated at Credit Suisse with a Neutral rating and $14 price target. Linaclotide is a potential best in class prescription drug. JB Hunt ( JBHT) initiated at Piper Jaffray. Initiated with an Overweight rating and $42 price target. Introduces 2010 EPS estimates of $1.52. Janus Capital ( JNS) upgraded at Citi to Buy from Hold on a tactical trading opportunity. Maintain $13 price target. Knight Transportation ( KNX) initiated at Piper Jaffray. Initiated with a Neutral rating and $23 price target. Introduces 2010 EPS estimates of $0.76. Sonoco Products ( SON) resumed and upgraded at Goldman with a Neutral rating and $34 price target. Stock is already largely pricing in a cyclical earnings recovery. Smith & Wesson ( SWHC) upgraded at Merriman from Neutral to Buy. Company had a strong quarter and should benefit from an improving backlog.